There’s a new player in the battle against viral disease. Icosavax, a new company launched under $51 million in investments led by Qiming Venture Partners USA, along with Sanofi Ventures, NanoDimension, and Adams Street Partners, is on its way to developing safe, effective vaccines to fight infectious diseases, address medical needs, and, ultimately, help reduce healthcare costs all around...
Sorry, you need to subscribe to read this article.
If you would like to access this article, please subscribe below.
Premium subscribers receive complete access to our site content which includes market research and insights as well as coverage of the most important news, issues and events related to the healthcare technology industry.